Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 22 Jun 2021 |

Image: X-Ray Blood Irradiator RS 3400 (Photo courtesy of Rad Source Technologies)
Rad Source Technologies (Buford, GA, USA), a supplier of commercial X-ray radiation products designed to replace self-shielded gamma irradiators, highlighted its newly redesigned RS 3400 Blood Irradiator at MEDLAB Middle East 2021.
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Latest MEDLAB 2021 News
- Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreMolecular Diagnostics
view channel
Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more









